tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

TRVI Stock Latest News

Trevi Therapeutics price target raised to $12 from $9 at Oppenheimer
The FlyTrevi Therapeutics price target raised to $12 from $9 at Oppenheimer
2d ago
TRVI
Trevi Therapeutics price target raised to $12 from $8 at Stifel
PremiumThe Fly
Trevi Therapeutics price target raised to $12 from $8 at Stifel
3d ago
TRVI
Trevi Therapeutics trial analysis ‘best case outcome,’ says Needham
PremiumThe Fly
Trevi Therapeutics trial analysis ‘best case outcome,’ says Needham
2M ago
TRVI
JonesResearch reiterates Buy rating on Trevi following positive CORAL update
PremiumThe Fly
JonesResearch reiterates Buy rating on Trevi following positive CORAL update
2M ago
TRVI
Trevi Therapeutics Phase IIb update a major de-risking event, says B. Riley
PremiumThe Fly
Trevi Therapeutics Phase IIb update a major de-risking event, says B. Riley
2M ago
TRVI
H.C. Wainwright ups Trevi Therapeutics target after ‘best-case’ for CORAL
PremiumThe FlyH.C. Wainwright ups Trevi Therapeutics target after ‘best-case’ for CORAL
2M ago
TRVI
Trevi Therapeutics provides update on Phase 2b trial of Haduvio in IPF
Premium
The Fly
Trevi Therapeutics provides update on Phase 2b trial of Haduvio in IPF
2M ago
TRVI
Trevi Therapeutics price target raised to $9 from $8 at JonesResearch
Premium
The Fly
Trevi Therapeutics price target raised to $9 from $8 at JonesResearch
3M ago
TRVI
Trevi Therapeutics selloff on data unwarranted, says H.C. Wainwright
PremiumThe Fly
Trevi Therapeutics selloff on data unwarranted, says H.C. Wainwright
3M ago
TRVI
Trevi Therapeutics announces results from HAP study of oral nalbuphine
PremiumThe Fly
Trevi Therapeutics announces results from HAP study of oral nalbuphine
3M ago
TRVI
Trevi Therapeutics Reports Q3 2024 Progress and Financials
PremiumCompany Announcements
Trevi Therapeutics Reports Q3 2024 Progress and Financials
4M ago
TRVI
Trevi Therapeutics reports Q3 EPS (13c), consensus (12c)
PremiumThe Fly
Trevi Therapeutics reports Q3 EPS (13c), consensus (12c)
4M ago
TRVI
Stifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
PremiumThe FlyStifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
4M ago
TRVI
Stifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
Premium
The Fly
Stifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
4M ago
TRVI
Trevi Therapeutics completes enrollment for Phase 2a RIVER trial
Premium
The Fly
Trevi Therapeutics completes enrollment for Phase 2a RIVER trial
4M ago
TRVI
Trevi Therapeutics provides update on Haduvio’s clinical development program
PremiumThe Fly
Trevi Therapeutics provides update on Haduvio’s clinical development program
5M ago
TRVI
Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update
PremiumThe Fly
Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update
5M ago
PEV
IRIX
Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress
PremiumCompany Announcements
Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress
5M ago
8K
TRVI
Trevi Therapeutics appoints James Cassella Chief Development Officer
PremiumThe Fly
Trevi Therapeutics appoints James Cassella Chief Development Officer
5M ago
TRVI
Trevi Therapeutics’ Haduvio shows cough relief efficacy in Phase 2a trial
PremiumThe FlyTrevi Therapeutics’ Haduvio shows cough relief efficacy in Phase 2a trial
5M ago
TRVI
Trevi Therapeutics assumed with an Outperform at Leerink
Premium
The Fly
Trevi Therapeutics assumed with an Outperform at Leerink
6M ago
TRVI
Abercrombie upgraded, Dollar General downgraded: Wall Street’s top analyst calls
Premium
The Fly
Abercrombie upgraded, Dollar General downgraded: Wall Street’s top analyst calls
6M ago
CM
DG

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >